Home/Filings/4/0001104659-25-015745
4//SEC Filing

Brewer Joanna Elizabeth 4

Accession 0001104659-25-015745

CIK 0001621227other

Filed

Feb 19, 7:00 PM ET

Accepted

Feb 20, 5:34 PM ET

Size

8.7 KB

Accession

0001104659-25-015745

Insider Transaction Report

Form 4
Period: 2025-02-20
Brewer Joanna Elizabeth
Chief Scientific Officer
Transactions
  • Award

    Option to purchase Ordinary Shares

    2025-02-20+1,612,0321,612,032 total
    Exercise: $0.10Exp: 2035-02-20Ordinary Shares (1,612,032 underlying)
  • Award

    Option to purchase Ordinary Shares

    2025-02-20+1,074,6961,074,696 total
    Exercise: $0.00Exp: 2035-02-20Ordinary Shares (1,074,696 underlying)
Footnotes (4)
  • [F1]The exercise price was converted from GBP0.08 based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.
  • [F2]Exercisable as to 403,008 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in monthly installments of 33,582 Ordinary Shares on the twentieth of each month from March 20, 2026 through January 20, 2028 and 33,654 Ordinary Shares on February 20, 2029.
  • [F3]The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of U.S.$ 1.257137 to GBP1.00. The actual exercise price will be the pounds sterling amount.
  • [F4]Exercisable as to 268,674 Ordinary Shares on February 20, 2026 and will be exercisable as to the remainder in annual installments of 268,674 Ordinary Shares on the twentieth of each February from February 20, 2027 through February 20, 2029.

Issuer

Adaptimmune Therapeutics PLC

CIK 0001621227

Entity typeother

Related Parties

1
  • filerCIK 0001923834

Filing Metadata

Form type
4
Filed
Feb 19, 7:00 PM ET
Accepted
Feb 20, 5:34 PM ET
Size
8.7 KB